Goodwill and Other Intangible Assets Goodwill (Tables)

9 Months Ended

Sep. 30, 2013

Goodwill [Line Items]

Schedule of Goodwill [Table Text Block]

The following represents our goodwill balance by new global reportable segment. We restated the prior period information to conform to the current presentation:

(in millions)	Cardiovascular		Rhythm Management			MedSurg		Total
Balance as of December 31, 2012 (restated)	$	3,249	$	577		$	2,147	$	5,973
Purchase price adjustments	3		—			—		3
Goodwill acquired	—		—			—		—
Goodwill written off	—		(423		)	—		(423		)
Balance as of September 30, 2013	$	3,252	$	154		$	2,147	$	5,553

The following is a rollforward of accumulated goodwill write-offs by global reportable segment. We restated the prior period information to conform to the current period presentation:

(in millions)	Cardiovascular			Rhythm Management			MedSurg			Total
Accumulated write-offs as of December 31, 2012 (restated)	$	(1,479	)	$	(6,537	)	$	(1,461	)	$	(9,477	)
Goodwill written off	—			(423		)	—			(423		)
Accumulated write-offs as of September 30, 2013	$	(1,479	)	$	(6,960	)	$	(1,461	)	$	(9,900	)

Goodwill

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill as of September 30, 2013 and December 31, 2012 is as follows:

	As of
	September 30, 2013					December 31, 2012
	Gross Carrying		Accumulated Amortization/			Gross Carrying		Accumulated Amortization/
(in millions)	Amount		Write-offs			Amount		Write-offs
Amortizable intangible assets
Technology-related	$	8,118	$	(3,254	)	$	8,020	$	(3,005	)
Patents	504		(322		)	559		(352		)
Other intangible assets	815		(465		)	810		(428		)
	$	9,437	$	(4,041	)	$	9,389	$	(3,785	)
Unamortizable intangible assets
Goodwill	$	15,453	$	(9,900	)	$	15,450	$	(9,477	)
Technology-related	197		—			242		—
	$	15,650	$	(9,900	)	$	15,692	$	(9,477	)

Impairment of Intangible Assets [Member]

Goodwill [Line Items]

Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block]

In-process research and development fair value is measured using projected revenues, projected expenses, discount rates, and

probability of expected launch. The nonrecurring Level 3 fair value measurements of the impairment analysis performed in the second quarter of 2013 included the following significant unobservable inputs:

Intangible Asset	Valuation Date	Fair Value	Valuation Technique	Unobservable Input	Rate
In-Process R&D	June 30, 2013	$178 million	Income Approach - Excess Earnings Method	Discount Rate	16.5%